Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|August 4, 2026 (Updated: July 30, 2026)

The BioPharm Brief: Algorithms, Approvals, and Autoimmunity

Listen
0:00 / 0:00

This episode of The BioPharm Brief explores three stories shaping biopharma today: an AI-driven licensing deal for a next-generation bispecific ADC, an FDA regulatory milestone for BOTOX Cosmetic, and the first patients dosed with a trispecific T-cell engager for autoimmune disease.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today we're looking at three stories that highlight how innovation continues to reshape drug development, from artificial intelligence guiding oncology licensing decisions to expanding indications for established biologics and new approaches to treating autoimmune disease.

First, Pathos AI has entered a global licensing agreement with Jiangsu Alphamab Biopharmaceuticals for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate, or ADC. Under the agreement, Pathos gains rights to develop and commercialize the therapy outside Greater China, with the deal including a $125 million upfront payment and the potential for more than $2 billion in milestone payments. The candidate was selected using Pathos' proprietary Foundry AI platform, which analyzes biological, clinical, and real-world data to identify promising therapeutic opportunities. JSKN016 is already in phase III testing for triple-negative breast cancer, making this another example of AI being used to guide portfolio decisions as well as drug discovery.

Next, the FDA has accepted Allergan Aesthetics' supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence in adults. If approved, the indication would make Botox Cosmetic the first neurotoxin specifically approved in the United States for this condition and would add a fifth aesthetic indication to the product's label. The submission is supported by two phase III studies that met their primary endpoints, demonstrating significant improvements in facial contour compared with placebo while maintaining a safety profile consistent with the product's established uses.

Finally, Oblenio Bio has dosed the first patients in a phase 1a trial evaluating LBL-051, a trispecific T-cell engager designed to target BCMA, CD19, and CD3 in refractory autoimmune diseases. Unlike autologous CAR T-cell therapies, LBL-051 is being developed as an off-the-shelf therapy intended to deplete both B cells and plasma cells, with the goal of achieving a more durable immune reset. The first-in-human study will evaluate safety, tolerability, pharmacodynamic biomarkers, and early signs of clinical activity across multiple autoimmune conditions.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Pathos AI is expanding its oncology pipeline through an AI-guided licensing agreement for a Phase III bispecific ADC.
  • The FDA has accepted an sBLA that could expand Botox Cosmetic's approved aesthetic indications.
  • Oblenio Bio has begun first-in-human testing of a trispecific T-cell engager designed to reset the immune system in autoimmune disease.

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more